US › Healthcare

LB Pharmaceuticals Inc Common Stock (LBRX)

US · Healthcare · Biotechnology

$45.00+5.04%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-19.1M
Profit YoY
-274.5%
EPS
$-0.67
EPS estimate
$-0.70

EPS came in at -0.67 against a street estimate of -0.70 — a beat of 3.6%.

Key statistics

Market cap
$1.15B
Forward P/E
0.0
P/B
3.04
Book value
$13.21
EPS (TTM)
$-1.36
52-week high
$44.33
52-week low
$13.36
50-day MA
$31.32
200-day MA
$24.79

Analyst view

with an average price target of $45.88.

Shareholding

Insiders
0.27%
Institutions
107.57%

Largest institutional holders

FundStake
Deep Track Capital, LP11.69%
BlackRock Inc8.62%
RA Capital Management, LLC7.70%
TCG Crossover Management, LLC6.41%
COMMODORE CAPITAL LP5.23%
Caligan Partners LP5.01%
JPMorgan Chase & Co4.98%
Spruce Street Capital LP4.80%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for LB Pharmaceuticals Inc Common Stock — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.